![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » The European Medicines Agency Approves Aripiprazole for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents
The European Medicines Agency Approves Aripiprazole for the Treatment of Moderate to Severe Manic Episodes in Bipolar I Disorder in Adolescents
February 6, 2013
Otsuka Pharmaceutical announced that the European Medicines Agency has approved a label extension for aripiprazole for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 and older.
Otsuka Pharmaceutical
Otsuka Pharmaceutical
Upcoming Events
-
21Oct